BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 33870843)

  • 1. Pneumocystis jirovecii: a review with a focus on prevention and treatment.
    Weyant RB; Kabbani D; Doucette K; Lau C; Cervera C
    Expert Opin Pharmacother; 2021 Aug; 22(12):1579-1592. PubMed ID: 33870843
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
    Kitazawa T; Seo K; Yoshino Y; Asako K; Kikuchi H; Kono H; Ota Y
    J Infect Chemother; 2019 May; 25(5):351-354. PubMed ID: 30711257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation.
    Diri R; Anwer F; Yeager A; Krishnadasan R; McBride A
    Transpl Infect Dis; 2016 Feb; 18(1):63-9. PubMed ID: 26606757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
    Urbancic KF; Pisasale D; Wight J; Trubiano JA
    Transpl Infect Dis; 2018 Dec; 20(6):e12968. PubMed ID: 30030892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population.
    Avino LJ; Naylor SM; Roecker AM
    Ann Pharmacother; 2016 Aug; 50(8):673-9. PubMed ID: 27242349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study.
    Helweg-Larsen J; Benfield T; Atzori C; Miller RF
    J Antimicrob Chemother; 2009 Dec; 64(6):1282-90. PubMed ID: 19858161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumocystis jirovecii Pneumonia in a Liver Transplant Recipient With an Adverse Reaction to Trimethoprim/Sulfamethoxazole Treated With a Sulfonamide Desensitization Protocol: Case Report.
    Baran K; Furmańczyk-Zawiska A; Wieczorek-Godlewska R; Nitek P; Durlik M
    Transplant Proc; 2024 May; 56(4):1000-1005. PubMed ID: 38760300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High incidence of Pneumocystis jirovecii pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era.
    Evernden C; Dowhan M; Dabas R; Chaudhry A; Kalra A; Dharmani-Khan P; Gregson D; Johnson A; Jupp J; Jimenez-Zepeda V; Jamani K; Duggan P; Tay J; Khan F; Daly A; Storek J
    Cytotherapy; 2020 Jan; 22(1):27-34. PubMed ID: 31889628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twice weekly prophylaxis with trimethoprim/sulfamethoxazole for
    Awad M; Sierra CM; Mesghali E; Bahjri K
    J Oncol Pharm Pract; 2021 Dec; 27(8):1936-1939. PubMed ID: 33307970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A regimen based on the combination of trimethoprim/sulfamethoxazole with caspofungin and corticosteroids as a first-line therapy for patients with severe non-HIV-related pneumocystis jirovecii pneumonia: a retrospective study in a tertiary hospital.
    Li H; Lu Y; Tian G; Wu Y; Chen T; Zhang J; Hu N; Wang X; Wang Y; Gao L; Yan J; Zhou L; Shi Q
    BMC Infect Dis; 2024 Jan; 24(1):152. PubMed ID: 38297200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.
    Prosty C; Katergi K; Sorin M; Rjeily MB; Butler-Laporte G; McDonald EG; Lee TC
    Clin Microbiol Infect; 2024 Jul; 30(7):866-876. PubMed ID: 38583518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumocystis jirovecii Pneumonia Prophylaxis with Intravenous Pentamidine in Adult Allogeneic Hematopoietic Stem Cell Transplant Patients.
    McCollam S; Lewis JS; Bubalo J; Diaz A
    Antimicrob Agents Chemother; 2022 Nov; 66(11):e0083322. PubMed ID: 36214573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review.
    Huang YS; Yang JJ; Lee NY; Chen GJ; Ko WC; Sun HY; Hung CC
    Expert Rev Anti Infect Ther; 2017 Sep; 15(9):873-892. PubMed ID: 28782390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors and clinical efficacy of second-line treatments of Pneumocystis jirovecii pneumonia for non-HIV patients after first-line treatment failure.
    Liu A; Sun R; Cao G; Liu X; Zhu H; Yang J
    BMC Infect Dis; 2022 Jun; 22(1):546. PubMed ID: 35701759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switch to atovaquone and subsequent re-challenge with trimethoprim-sulfamethoxazole for Pneumocystis prophylaxis in a kidney transplant population.
    McLaughlin MM; Galal A; Richardson CL; Sutton SH; Barr VO; Patel N; Mitchell P; Stosor V
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28833985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients.
    Tu GW; Ju MJ; Xu M; Rong RM; He YZ; Xue ZG; Zhu TY; Luo Z
    Nephrology (Carlton); 2013 Nov; 18(11):736-42. PubMed ID: 24571744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Options in the management of pneumonia caused by Pneumocystis carinii in patients with acquired immune deficiency syndrome and intolerance to trimethoprim/sulfamethoxazole.
    Korraa H; Saadeh C
    South Med J; 1996 Mar; 89(3):272-7. PubMed ID: 8604455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Pneumocystis jirovecii pneumonia prophylaxis on hematologic toxicity in patients receiving chemoradiation for primary brain tumors.
    Arnold LM; Hoshina Y; Lee H; Colman H; Mendez J
    J Neurooncol; 2024 Mar; 167(1):211-217. PubMed ID: 38363493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia.
    Salzer HJF; Schäfer G; Hoenigl M; Günther G; Hoffmann C; Kalsdorf B; Alanio A; Lange C
    Respiration; 2018; 96(1):52-65. PubMed ID: 29635251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of prophylaxis choice on risk of pneumocystis pneumonia in children with cancer: A case-control study.
    Geerlinks AV; Campigotto A; Science M; Gupta S
    Eur J Cancer; 2020 Nov; 140():71-75. PubMed ID: 33059195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.